Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries-Reference-Cited by-同舟云学术

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries

Published:2020-06-05 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Inotai András,Tomek Dominik,Niewada Maciej,Lorenzovici László,Kolek Martin,Weber Jakub,Kurrat Anne-Katrin,Kiss Emese Virág,Kaló Zoltán

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference40 articles.

1. Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation;Balanescu;Rheumatol. Int.,2013

2. Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study;Batko;Arch. Med. Sci.,2019

3. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities;Baumgart;Front. Pharmacol.,2019

4. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK;Brennan;Rheumatol. (Oxford),2004

5. Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania;Codreanu,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-18

2. Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study;Health Science Reports;2023-03

3. Association of exogenous factors with the access to innovative pharmaceutical products in Hungary;PLOS ONE;2023-02-06

4. Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis;Frontiers in Pharmacology;2022-12-16

5. Outcome-based reimbursement in Central-Eastern Europe and Middle-East;Frontiers in Medicine;2022-09-23